PRECISION CAPITAL
ADVANCING
PRECISION HEALTH®

A PURPOSE-BUILT VENTURE FIRM

We combined accomplished investment professionals and operators with a proprietary national medical network platform to create the most unique venture firm in life sciences. MEC deploys precision capital to nurture and advance the precision health innovations that solve the biggest, most complex medical problems.

Proprietary Network of the World’s Leading Physician Scientists >
Team of Experienced VCs, Company Creators and Operators >

MEDICAL EXCELLENCE CAPITAL

A Differentiated Early-Stage Life Sciences Venture Fund >

ADVANCING THE PRECISION HEALTH DECADE

At MEC, we believe the technologies created in this decade will lead to a golden age in innovation within the life sciences space. MEC invests in company creation, seed, Series A, and Series B opportunities where technology and novel approaches are transformative for patient care and directly address large, unmet needs. Our areas of focus include, but are not limited to:

AI TO
ADVANCE DRUG
DISCOVERY
CELL AND GENE THERAPY
PRECISION MEDICINE
REGENERATIVE MEDICINE
SYNTHETIC BIOLOGY

OUR PORTFOLIO

Aspen Neuroscience
Aspen Neuroscience
Active
Immunitas Therapeutics
Active
Nobias Therapeutics
Active
ProJenX
ProJenX
Active
View All

NEWS & BLOG

View the latest posts and investment news from MEC.

Press Release
ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors
Read More
Press Release
Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meeting
Read More
Press Release
AVILAR THERAPEUTICS TO PRESENT NEW DATA FOR ATAC EXTRACELLULAR PROTEIN DEGRADERS AT TARGETED PROTEIN DEGRADATION SUMMIT
Read More
View All

TAKE THE NEXT STEP

Contact us today for more information about MEC.

GET IN TOUCH